Roche Obtains Positive Data on Early-Stage Breast Cancer Treatment
09 December 2023 - 4:56AM
Dow Jones News
By Andrea Figueras
Roche said that it has received positive long-term follow-up
data and significant overall survival benefit from the Katherine
study, which examines people with early-stage breast cancer.
The study evaluated the efficacy and safety of Kadcyla versus
Herceptin as an adjuvant therapy, the Swiss pharmaceutical company
said on Friday, pointing out that data showed continued benefit for
the first one as it reduced the risk of disease recurrence or death
from any cause by 46% compared with Herceptin.
"Katherine results reinforce Kadcyla as the standard of care for
this population, with more than 82,000 people treated to date,"
Roche said.
At three years, 88.3% of people treated with Kadcyla didn't have
their breast cancer return compared with 77% treated with
Herceptin, an absolute improvement of 11.3%, the company said.
Kadcyla is approved in 113 countries and is the standard of care
for people with HER2-positive early-stage breast cancer with
residual invasive disease after a pre-surgery treatment, it
said.
Write to Andrea Figueras at andrea.figueras@wsj.com
(END) Dow Jones Newswires
December 08, 2023 12:40 ET (17:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Oct 2024 to Nov 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Nov 2023 to Nov 2024
